Omixon Receives IVDR approval for NanoTYPE™ CE IVDR Pioneering Transplant Diagnostic with the First CE IVDR Kit based on Oxford Nanopore Technologies

11/06/2024

Press Release June 11, 2024 Budapest, Hungary Omixon Receives IVDR approval for NanoTYPE™ CE IVDR Pioneering Transplant Diagnostic with the First CE IVDR Kit based on Oxford Nanopore Technologies Omixon has received In Vitro Diagnostic Regulation (IVDR) approval of NanoTYPE™, an innovative high resolution multiplex 11 loci...

Omixon to Launch HoloGRAFT ONE, A Research-Use-Only Donor-derived Cell-free DNA Kit and Software for Post-transplant Monitoring

28/05/2024

Omixon to Launch HoloGRAFT ONE, A Research-Use-Only Donor-derived Cell-free DNA Kit and Software for Post-transplant Monitoring.

Werfen to acquire Omixon expanding its portfolio in transplant diagnostics

15/05/2024

Barcelona, Spain May 15, 2024.- Werfen announced today that it has agreed to acquire Omixon, a privately held corporation with an innovative portfolio in transplant diagnostics headquartered in Budapest, Hungary. The acquisition will allow Werfen to expand its portfolio of transplant diagnostics solutions for hospitals and clinical laboratories.

Omixon at EFI 2024 Geneva

25/04/2024

Excitement is building as we gear up for this year’s EFI Conference in Geneva. Year after year EFI serves as a dynamic platform for exchanging ideas, networking, and exploring collaborations that can drive the field forward. Be sure to visit the Omixon booth first to see NanoTYPE and NanoTYPER...

Omixon at EFI 2023

13/02/2023

We are happy to announce that Omixon will attend the 36th European Immunogenetics & Histocompatibility Conference in Nantes on 26-29 April 2023. The theme of the conference this year will be Big Data in Immunogenetics at The Crossroad of Care, Tools & Research. Visit the Omixon Booth #5 and...